ABSTRACT
The spectrum of synthetic pharmaceutical treatment options for patients presenting with lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH) has expanded considerably over the last decade and this has been accompanied by an increase in the use of plant-derived therapies.1,2 At the same time, a worldwide decrease in classical operative procedures has been reported, with rates of transurethral resection of the prostate (TURP) and open prostatectomy falling by up to 50% in some countries.3
